BRASH syndrome: а clinical case

The article describes a clinical case of BRASH syndrome in patient M., born in 1938, suffering from hypertension and diabetes mellitus. The patient took bisoprolol, eplerenone, azilsartan medoxomil, lercanidipine hydrochloride daily. She was admitted to the hospital complaining of weakness, eyes darkening, nausea, short-term loss of consciousness, rare pulse, diarrhea the day before. During the examination, she was diagnosed with severe sinus bradycardia (38 beats/min) and transient first-degree atrioventricular (AV) block, stage 4 chronic kidney disease of with hyperkalemia (potassium 5.53-6.12 mmol/l). Pulse-reducing drugs, blockers of the renin-angiotensin-aldosterone system were canceled for the patient, 0.9% sodium chloride solution and furosemide were prescribed. The patient was discharged in a satisfactory condition. This clinical example meets the criteria of BRASH syndrome, since against the background of taking an AV node blocker in a small dose, a patient with chronic kidney disease with mild to moderate hyperkalemia developed severe sinus bradycardia and transient grade 1 AV block. The trigger factors for BRASH syndrome development of were azilsartan medoxomil and eplerenone intake, as well as hypovolemia due to diarrhea.

1. Kawabata M, Yokoyama Y, Sasaki T, et al. Severe iatrogenic bradycardia related to the combined use of beta-blocking agents and sodium channel blockers. Clin Pharmacol. 2015;7:29-36. DOI:10.2147/CPAA.S77021.

2. Shin J, Pletcher MJ. Risk of emergent bradycardia associated with the use of carvedilol and metoprolol in routine clinical practice. Am J Med. 2013;126(9):805-10.e5. DOI:10.1016/j.amjmed.2013.02.030.

3. Bonvini RF, Hendiri T, Anwar A. Sinus arrest and moderate hyperkalemia. Ann Cardiol Angeiol (Paris). 2006;55(3):161-3. DOI:10.1016/j.ancard.2005.10.001.

4. Hegazi MO, Aldabie G, Al-Mutairi S, El Sayed A. Junctional bradycardia with verapamil in renal failure-care required even with mild hyperkalaemia. J Clin Pharm Ther. 2012;37(6):726-8. DOI:10.1111/j.1365-2710.2012.01352.x.

5. Farkas JD, Long B, Koyfman A, Menson K. BRASH Syndrome: Bradycardia, Renal Failure, AV Blockade, Shock, and Hyperkalemia. J Emerg Med. 2020;59(2):216-23. DOI:10.1016/j.jemermed.2020.05.001.

6. Bailuni Neto JJ, Siqueira BL, Machado FC, et al. BRASH Syndrome: A Case Report. Am J Case Rep. 2022;23:e934600. DOI:10.12659/AJCR.934600.

7. Wong CK, Jaafar MJ. Bradycardia, renal failure, atrioventricular nodal blockade, shock, and hyperkalemia: An important syndrome to recognize. Turk J Emerg Med. 2021;21(2):86-89. DOI:10.4103/2452-2473.309138.

8. Gebray HM, Abeje AE, Boye AT. BRASH syndrome with a complete heart block — a case report. BMC Cardiovasc Disord. 2024;24(1):114. DOI:10.1186/s12872-024-03782-6.

9. Sattar Y, Bareeqa SB, Rauf H, et al. Bradycardia, Renal Failure, Atrioventricular-nodal Blocker, Shock, and Hyperkalemia Syndrome Diagnosis and Literature Review. Cureus. 2020;12(2):e6985. DOI:10.7759/cureus.6985.

10. Perepech NB, Mihajlova IE. Bisoprolol: pharmacological properties and clini­­cal application. RMeJ. 2004;(4):225-32. (In Russ.)

11. Yakushin CC, Nikulina NN, Filippov EV, et al. Results of the pilot part of the cardiac drug overdoses hospital registry (storm): focus on drug-induced bradycardia. I. P. Pavlov Russian Medical Biological Herald. 2020;28(2):153-63. (In Russ.) DOI:10.23888/PAV-LOVJ2020282153-163.

12. Lizyness K, Dewald O. BRASH Syndrome. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK570643/

13. Palmisano P, Accogli M, Zaccaria M, et al. Relationship between sea­sonal weather changes, risk of dehydration, and incidence of severe bradyarrhythmias requiring urgent temporary transvenous cardiac pacing in an elderly population. Int J Biometeorol. 2014;58(7):1513-20. DOI:10.1007/s00484-013-0755-7.

14. Fomina OA, Pereverzeva KG. The development of hyperkalemia in a comor­bid patient against the background of uncontrolled combined use of renin-angiotensin system blockers and mineralocorticoid receptor antagonists. Effective Pharmacotherapy. 2023;(19):24-8. (In Russ.) DOI:10.33978/2307-3586-2023-19-53-24-28.

15. Poselyugina OB, Mikhailova MI. Prognostic value of hyperkalemia: treat­ment options. International Research Journal. 2021;(1-3):57-60. (In Russ.) DOI:10.23670/IRJ.2021.103.1.064.

16. Vishneva EM, Dyadyakina AA, Poteryaeva NE. The problem of hyperkalemia in patients with chronic heart failure. Universum: Medicine and Pharmacology. 2021;(5):8-11 (In Russ.) DOI:10.32743/UniMed.2021.77.5.11615.

17. Palmer BF, Clegg DJ. Diagnosis and treatment of hyperkalemia. Cleve Clin J Med. 2017;84(12):934-942. DOI:10.3949/ccjm.84a.17056.

18. al-Khafaji M, al-Salem IH. Nifedipine induced bradycardia in a patient with autonomic neuropathy. Jpn Heart J. 1989;30(5):679-683. DOI:10.1536/ihj.30.679.

19. Taira N, Narimatsu A. Effects of nifedipine, a potent calcium antagonistic coronary vasodilator on atrioventricular conduction and blood flow in the isolated atrioventricular node preparation of the dog. Naunyn Schmiedebergs Arch Pharmacol. 1975;290(1):107-112. DOI:10.1007/BF00499993.

20. Sarkar S, Rapista N, Rout A, Chaudhary R. BRASH: Case Report and Review of Literature. Hearts. 2021;2(3):302-306. DOI:10.3390/hearts2030025.

21. Imburgio S, Johal A, Udongwo N, et al. BRASH Syndrome: A Case Report and Literature Review. Journal of Integrative Cardiology Open Access 2022:10.31487/j.jicoa.2022.03.05. DOI:10.31487/j.jicoa.2022.03.05.

22. Gromov MI, Fedorov AV, Mihalchuk MA, Zaev OE. Hyperkalaemia in the emergency diseases: practical guidelines. Emergency Medical Care. 2015;16(2):38-43 (In Russ.) DOI:10.24884/2072-6716-2015-16-2-38-43.

23. Shah P, Gozun M, Keitoku K, et al. Clinical characteristics of BRASH syndrome: Systematic scoping review. Eur J Intern Med. 2022;103:57-61. DOI:10.1016/j.ejim.2022.06.002.

24. Aziz EF, Javed F, Korniyenko A, et al. Mild hyperkalemia and low eGFR a tedious recipe for cardiac disaster in the elderly: an unusual reversible cause of syncope and heart block. Heart Int. 2011;6(2):e12. DOI:10.4081/hi.2011.e12.

25. Saeed S, Rajani R, Solheim E. A BRASH Diagnosis With a Timely Intervention. Curr Probl Cardiol. 2023;48(11):101984. DOI:10.1016/j.cpcardiol.2023.101984.

26. Ahee P, Crowe AV. The management of hyperkalaemia in the emergency department. J Accid Emerg Med. 2000;17(3):188-91. DOI:10.1136/emj.17.3.188.

27. Majeed H, Khan U, Khan AM, et al. BRASH Syndrome: A Systematic Review of Reported Cases. Curr Probl Cardiol. 2023;48(6):101663. DOI:10.1016/j.cpcardiol.2023.101663.

28. Vishnu VK, Jamshed N, Amrithanand VT, Thandar S. BRASH Syndrome: A Case Report. J Emerg Med. 2021;60(6):818-22. DOI:10.1016/j.jemermed.2021.01.033.

29. Ferreira JP, Butler J, Rossignol P, et al. Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75(22):2836-50. DOI:10.1016/j.jacc.2020.04.021.

30. Kovesdy CP. Outcomes Associated With Potassium Abnormalities in CKD: It Is Time to Move to Clinical Trials. Am J Kidney Dis. 2023;82(3):251-3. DOI:10.1053/j.ajkd.2023.05.002.

31. Shionoiri H, Naruse M, Minamisawa K, et al. Fosinopril. Clinical phar­macokinetics and clinical potential. Clin Pharmacokinet. 1997;32(6):460-80. doi:10.2165/00003088-199732060-00003.